Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
01. Juni 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...